Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 79,900 shares at $41.52 ($3.2M) on 2024-08-07, disclosed to the SEC on 2024-08-09.
Scheduled sale ($3.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.40 | 32,233 | $1.3M | 40.1% |
| 2 | $40.40 | 32,233 | $1.3M | 40.1% |
| 3 | $41.52 | 7,667 | $318K | 9.8% |
| 4 | $41.52 | 7,667 | $318K | 9.8% |
| 5 | $42.17 | 100 | $4K | 0.1% |
| Total | $40.62 avg | 79,900 |
| $3.2M |
| 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |